- The P-III PANORAMA Trial involves assessing of Eylea (aflibercept) vs sham injection in 402 patients with moderately severe to severe NPDR in without DME for 16 wks. or 8 wks.
- P-III study results: Patients with ≥2‑step improvement on DRSS score (65%, 80% vs 15%); Patients who developed a vision-threatening event (10%, 11% vs 41%); patients with severe non-proliferative diabetic retinopathy (NPDR) (15%, 15% vs 53%); Subgroup with moderately severe NPDR (8%, 10%, vs 36%)
- Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor, indicated for Neovascular (Wet) AMD, Macular Edema RVO & DME, with expected PDUFA on 13 May, 2019 for DR
Click here to read full press release/ article | Ref: PRNewswire | Image: Limerick Leader